Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	32D1091841	04/30/2024
Name of Provider or Supplier	**Street Address, City, State**	
Rio Grande Dermatology	4545 Alameda Blvd Ne, Ste G, Albuquerque, NM	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An onsite initial survey conducted on April 30, 2024, at Rio Grande Dermatology found the laboratory to be in compliance with the CLIA regulations found at 42 CFR, Part 493 Laboratory Requirements, with standard deficiencies cited.
D5473	CONTROL PROCEDURES CFR(s): 493.1256(e)(2)(g) (e) For reagent, media, and supply checks, the laboratory must do the following: (e) (2) Each day of use (unless otherwise specified in this subpart), test staining materials for intended reactivity to ensure predictable staining characteristics. Control materials for both positive and negative reactivity must be included, as appropriate. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on review of laboratory policy, laboratory's Quality Control Log, and staff interview, the laboratory failed to define the intended reactivity of Hematoxylin and Eosin (H&E) quality control stain characteristics for 4 of 4 months (September through December) in 2023. Findings included: 1. Review of the laboratory's procedure titled "Frozen Section Quality Control", stated the following: "The surgeon will review this slide prior to any others and assess for fidelity of the staining process. Should no deficiencies be noted, the surgeon will sign 'P' in the daily log, indicating Pass." 2. Review of the laboratory forms titled "Quality Control Log", from September 2023 through December 2023 listed criteria as: "Hematoxylin should have crisp nucleus and sufficient counterstain (Eosin). The laboratory failed to define intended reactivity for H&E stain characteristics. 3. During an interview on 04/30 /2024 at 10:30 am, after review of the above results, the Laboratory Director confirmed the above findings.